Novavax publishes RSV protein nanoparticle vaccine candidate preclinical study

Novavax announced that the journal PLOS ONE published data from a preclinical study of its recombinant nanoparticle vaccine candidate against respiratory syncytial virus, demonstrating efficacy and safety in a well-established animal model. These data indicated that the use of an RSV fusion protein nanoparticle vaccine that induced high levels of specific neutralizing antibodies protected animals from both RSV replication and disease.

View Comments (0)